8-K: PROCEPT BioRobotics Exceeds Expectations with Strong Q3 Results and Increased 2024 Guidance

PROCEPT BioRobotics reported a 66% increase in revenue for the third quarter of 2024, driven by strong U.S. and international sales, and raised its full-year revenue and adjusted EBITDA guidance.

Summary

• PROCEPT BioRobotics announced its financial results for the third quarter of 2024, showing significant growth.
• Total revenue reached $58.4 million, a 66% increase compared to the same period last year.
• U.S. revenue grew by 62% to $52.2 million, with handpiece and consumable revenue up 74% to $29.6 million.
• International revenue saw a substantial increase of 122%, reaching $6.2 million.
• The company sold 45 robotic systems in the U.S. during the quarter, with an average selling price of approximately $432,000.
• Gross margin improved to a record 63.2%, up from 53.8% in the prior year period.
• The company increased its full-year 2024 revenue guidance to a range of $222.5 million to $223.0 million.
• Full-year gross margin guidance was increased to 61%.
• Adjusted EBITDA loss guidance for 2024 was improved to $60.0 million.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong revenue growth, improved gross margins, increased guidance, and successful product launch. The company is clearly performing well and exceeding expectations.

Positives

• The company experienced strong revenue growth across all segments, particularly in the U.S. and internationally.
• The increase in U.S. handpiece and consumable revenue indicates strong adoption and usage of their products.
• The sale of 45 robotic systems in the U.S. demonstrates continued market penetration.
• The significant improvement in gross margin to 63.2% shows improved profitability.
• The increased full-year revenue and adjusted EBITDA guidance reflects management's confidence in the company's performance.
• The company has a strong cash position with $199.8 million in cash, cash equivalents and restricted cash as of September 30, 2024.

Negatives

• Operating expenses increased to $59.3 million in Q3 2024, driven by sales and marketing and research and development expenses.
• The company reported a net loss of $21.0 million for the third quarter of 2024, although this is an improvement from the prior year.
• The company is still operating at a loss, with an adjusted EBITDA loss of $12.4 million for the quarter.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The company's forward-looking statements are based on current expectations and are not guarantees of future performance.
• Increased operating expenses could impact future profitability if not managed effectively.
• The company's reliance on non-GAAP measures like Adjusted EBITDA may not be directly comparable to other companies.

Future Outlook

The company has increased its full-year 2024 revenue guidance to a range of $222.5 million to $223.0 million, with a gross margin of approximately 61% and an adjusted EBITDA loss of $60.0 million.

Management Comments

• Reza Zadno, Chief Executive Officer, stated he is extremely proud of the entire PROCEPT team for their collective effort and execution in launching HYDROS in the third quarter.
• Management highlighted the successful conversion of the third quarter capital pipeline, manufacturing of sufficient commercial product, training of clinical teams, and effective management of customer relationships.

Industry Context

This announcement reflects the growing demand for robotic surgical solutions in urology, with PROCEPT BioRobotics positioned as a key player in the market. The company's focus on AI-powered technology and clinical evidence supports its competitive advantage.

Comparison to Industry Standards

• Intuitive Surgical, a leader in robotic surgery, reported a 12% increase in system placements in their most recent quarter, while PROCEPT reported 45 system sales in the US alone, indicating a strong growth trajectory.
• Globally, the surgical robotics market is experiencing double-digit growth, and PROCEPT's 66% revenue increase significantly outpaces the industry average.
• Companies like Stryker and Medtronic also operate in the broader surgical device market, but PROCEPT's focus on urology and Aquablation therapy provides a unique niche.
• The gross margin of 63.2% is competitive with other medical device companies, indicating efficient operations and pricing strategies.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees will be encouraged by the company's growth and success.
• Customers will benefit from the continued innovation and availability of the company's products.
• Suppliers will see increased demand for their products and services.

Next Steps

• The company will host a conference call to discuss the third quarter 2024 financial results on October 28, 2024.
• The company will continue to focus on commercializing the HYDROS Robotic System and expanding its market presence.

Key Dates

Keywords

surgical robotics, urology, Aquablation therapy, robotic systems, medical devices, revenue growth, gross margin, Adjusted EBITDA, HYDROS, PROCEPT BioRobotics